Natco Pharma witnessed a sharp rise in share prices on Friday after the company's marketing partner in the US, Breckenridge Pharmaceutical (BPI) has filed an Abbreviated New Drug Application (ANDA) for Everolimus 0.25mg, 0.5mg, and 0.75mg tablets.

Natco and BPI believe that its Paragraph IV ANDA was filed on the First-to-File date and expects to be the only generic that is entitled to the 180-day exclusivity period.

Shares of the company gained Rs 53.9, or 3.93%, to trade at Rs 1,424.00. The total volume of shares traded was 9,919 at the BSE (11.40 a.m., Friday).

The scrip has touched an intra-day high of Rs 1,430.70 and low of Rs 1,357.95. The total volume of shares traded at the BSE is 9,919.